Publication Name	World Journal of Clinical Oncology
Manuscript ID	104827
Country	India

Received	2025-01-08 04:58
Peer-Review Started	2025-01-08 04:58
To Make the First Decision
Return for Revision	2025-02-14 08:46
Revised	2025-02-17 11:35
Second Decision	2025-03-03 02:44
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-03-04 12:39
Articles in Press	2025-03-04 12:39
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-03-13 08:11
Publish the Manuscript Online	2025-03-26 10:16

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Observational Study
Article Title	Evaluating pregabalin in cancer patients with chronic neuropathic pain and depression: an observational case series
Manuscript Source	Unsolicited Manuscript
All Author List	Pinaki Chakraborty and Mrinal Borgohain
ORCID	Author(s) ORCID Number Mrinal Borgohain http://orcid.org/0000-0001-8909-1348
Funding Agency and Grant Number
Corresponding Author	Mrinal Borgohain, MD, Medical Affairs, MSN Laboratories, H. No. 2-91/10 & 11/MSN, Whitefields, Kondapur, Hyderabad 500084, Telangāna, India. mrinal.borgohain@msnlabs.com
Key Words	Pregabalin; Cancer; Neuropathic pain; Depression
Core Tip	The study found that pregabalin significantly reduced both pain intensity and depression severity in terminal cancer patients. Pain levels, as measured by the brief pain inventory, saw a 47.4% reduction, while depressive symptoms, assessed using the Hamilton depression rating scale, experienced a similar reduction of 47.0%. Side effects were manageable, with no severe adverse effects reported. These findings indicate that pregabalin holds promise as a treatment option to improve the quality of life in terminal cancer patients, though further research is needed to substantiate these results.
Publish Date	2025-03-26 10:16
Citation	<p>Chakraborty P, Borgohain M. Evaluating pregabalin in cancer patients with chronic neuropathic pain and depression: an observational case series. <i>World J Clin Oncol</i> 2025; 16(4): 104827</p>
URL	https://www.wjgnet.com/2218-4333/full/v16/i4/104827.htm
DOI	https://dx.doi.org/10.5306/wjco.v16.i4.104827

Full Article (PDF)	WJCO-16-104827-with-cover.pdf
STROBE Statement	104827-STROBE-statement.pdf
Manuscript File	104827_Auto_Edited_032719.docx
Answering Reviewers	104827-answering-reviewers.pdf
Audio Core Tip	104827-audio.m4a
Biostatistics Review Certificate	104827-biostatistics-statement.pdf
Conflict-of-Interest Disclosure Form	104827-conflict-of-interest-statement.pdf
Copyright License Agreement	104827-copyright-assignment.pdf
Signed Informed Consent Form(s) or Document(s)	104827-informed-consent-statement.pdf
Institutional Review Board Approval Form or Document	104827-institutional-review-board-statement.pdf
Non-Native Speakers of English Editing Certificate	104827-non-native-speakers.pdf
Peer-review Report	104827-peer-reviews.pdf
Scientific Misconduct Check	104827-scientific-misconduct-check.png
Scientific Editor Work List	104827-scientific-editor-work-list.pdf
CrossCheck Report	104827-crosscheck-report.pdf